L'intérêt à découvert pour Cutera donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Cutera. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Cutera (NASDAQ:CUTR) Stock, Rapport sur les intérêts à découvert

Cutera

Cutera Inc is a medical device company that specializes in designing, developing, manufacturing, marketing, and servicing laser and other energy-based aesthetics systems for practitioners internationally. Its products include enlighten, excel HR, excel V, Xeo and Trusculpt 3D among others. The company markets and sells its products under the trademarks such as Cutera, Acutip, Coolglide, Enlighten, Excel HR, Excel V, Genesis plus, Pico-genesis, Titan, Trusculpt, and Xeo among others. It derives the majority of its revenue from the United States segment. Its products enable medical practitioners to perform safe procedures including treatment for acne, body contouring, skin resurfacing and revitalization, hair and tattoo removal, removal of benign pigmented lesions, and vascular conditions.

Cutera Inc

U.S. stock futures fell on Thursday following Wednesday&#8217;s relief after a two-day fall. Futures of all four benchmark indices fell in premarket trading.
President Donald Trump&#8217;s administration postponed implementation of auto tariffs by one month on Wednesday after the tariffs on Canada, Mexico, and China were implemented on Tuesday.
Meanwhile, the 10-year Treasury yield stood at 4.30%, while the two-year yield was at 3.99%. According to the CME Group's FedWatch <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">tool</a>, there is a 93% chance that the Federal Reserve will keep interest rates unchanged for the March meeting.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-1.32%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-1.12%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.92%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.14%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Thursday. SPY dropped 1.15% to $576.35, and QQQ declined 1.33% to $495.34, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
Cues From The Last Session
Utilities and energy were the only sectors that declined on Wednesday, while the market witnessed a rally led by materials, consumer discretionary, industrials, and communication services sectors.
On the economic front, February&#8217;s ADP report showed that the private sector employment was up 77,000 jobs, with annual pay rising 4.7%. The S&amp;P Global US Composite PMI Output Index fell to 51.6 in February, down from 52.7 in January. It was the second successive month in which the PMI has fallen, and the latest reading was the lowest since last April.
Marvell Technology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) declined in after-hours following a disappointing guidance. Rigetti Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) also fell in after-hours as its revenue missed estimates.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>1.46%</td>
<td>18,552.73</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>1.12%</td>
<td>5,842.63</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>1.14%</td>
<td>43,006.59</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1.02%</td>
<td>2,100.75</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
A notable drop in the 10-year Treasury yield reflects market concerns about economic deceleration, said Scott Wren, senior global market strategist at Wells Fargo. Despite robust fourth-quarter earnings and previously strong growth, recent data paints a more cautious picture.
Wren attributes this shift to factors like lowered consumer sentiment, driven by tariff uncertainties and potential labor market weakness. He also points to a &#8220;pull-forward&#8221; effect, where companies and consumers accelerated purchases to avoid anticipated tariff-related price hikes, evidenced by record-high January trade deficits. Weather impacts further complicate the data.
However, Wren notes positive signs, including strong consumer spending on services and increased home purchase applications amid falling mortgage rates. While acknowledging a near-term economic slowdown, he anticipates solid growth in 2025.
&#8220;From our perspective, we see a slowing economy as something like a temporary air pocket in the nearer term, and we continue to expect solid economic growth in 2025. We see market uncertainties creating opportunities in both equities and fixed income as the year progresses. Be patient, but be ready to act.&#8221;
Analysts at BlackRock highlighted the &#8220;unusually uncertain policy environment,&#8221; which according to them requires different views across horizons.
&#8220;While U.S. corporate strength is our base case for now, we have seen the outlook evolve suddenly in recent years. We stand ready to pivot given uncertainty because of the economic transformation and U.S. policy now. We created our scenarios last year to help us navigate this volatile environment. While some of the incoming information on U.S. policy has been noisy, we expect that to become a concrete signal to adapt to,&#8221; stated the BlackRock note.
Reiterating confidence in AI-linked stocks, the analysts added, &#8220;AI-related shares have come under pressure from lingering investor worries about whether AI investment will pay off. Yet we think this is still the early phase of AI adoption and see room for the buildout winners to do well.&#8221;
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures">How to Trade Futures </a>
Upcoming Economic Data
Here&#8217;s what investors will keep on Thursday:
<ul>
<li>Initial jobless claims data for the week ended March 1 will be out by 8:30 a.m., ET.</li>
</ul>
<ul>
<li>U.S. productivity data for the fourth quarter and U.S. trade deficit data for January will be released at 8:30 a.m., ET as well.</li>
</ul>
<ul>
<li>January&#8217;s wholesale inventory data will be out by 10:00 a.m., ET.</li>
</ul>
<ul>
<li>Fed Governor Christopher Waller will speak at 3:30 p.m. and Atlanta Fed President Raphael Bostic will speak at 7:00 p.m.</li>
</ul>
Stocks In Focus:
<ul>
<li>BJ&#8217;s Wholesale Club Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) was up 0.01% in the premarket on Thursday ahead of its earnings, which will be released before the opening bell. Analysts expect it to report earnings of 88 cents per share on revenue of $5.32 billion.</li>
</ul>
<ul>
<li>Kroger Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) slipped 0.27% as Wall Street expects it to report quarterly earnings of $1.11 per share on revenue of $34.51 billion before the opening bell.</li>
</ul>
<ul>
<li>Macy&#8217;s Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) was 0.45% higher ahead of its earnings, which will be released before the opening bell. Analysts expect it to report earnings of $1.53 per share on revenue of $7.87 billion.</li>
</ul>
<ul>
<li>Hewlett Packard Enterprise Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) declined 1.54% ahead of its earnings, which will be released after the closing bell. Analysts expect it to report earnings of 49 cents per share on revenue of $7.82 billion.</li>
</ul>
<ul>
<li>Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) climbed 6.12% after its revenue of $720.9 million, up 14% year-over-year, beat the consensus estimate of $699.11 million.</li>
</ul>
<ul>
<li>Propetro Holding Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PUMP#NYSE">PUMP</a>) plunged 45.88% after its CFO, David Schorlemer, departed the company on March 3, 2025, after 4.5 years of leading financial growth and development.</li>
</ul>
<ul>
<li>AGM Group Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGMH#NASDAQ">AGMH</a>) surged 105.28% as it completed $5.4 million public offering to expand Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining operations.</li>
</ul>
<ul>
<li>Cutera Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares jumped 37.23% as it announced a plan to reduce debt by $400 million and raise $65 million on Wednesday.</li>
</ul>
<ul>
<li>Visionary Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GV#NASDAQ">GV</a>) gained 25.3% after the company received a financing consent letter worth $1 billion from Alfardan Group of Qatar to fund product R&amp;D and the development of PEGASUS new energy vehicles.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were trading higher in the early New York session by 0.36% to hover around $66.55 per barrel.
The gold spot index was down by 0.83% to $2,894.73 per ounce. Its last record high was at $2,956.37 per ounce. The Dollar Index was down 0.07% at the 104.204 level.
Asian markets closed higher on Thursday except Australia's ASX 200 index. India's S&amp;P BSE Sensex, China's CSI 300, South Korea's Kospi, Japan's Nikkei 225, and Hong Kong's Hang Seng index advanced. European markets were mostly lower in trade.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/03/44160509/starlinks-european-rival-up-over-600-since-trump-halted-ukraine-aid-now-plans-to-replace-e">Starlink&#8217;s European Rival, Up Over 600% Since Trump Halted Ukraine Aid, Now Plans To Replace Elon Musk&#8217;s Satellite Internet Service In War-Torn Nation</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

News

Futures

Forex

Economics

Pre-Market Outlook

Markets

Analyst Ratings

$BTC

AGMH

CUTR

MRVL

PUMP

RGTI

VEEV

US Stocks Likely To Open Lower After Wednesday's Blip: 'Be Patient, But Be Ready To Act,' Says Analyst As Market Uncertainties Can Create 'Opportunities'

Cutera Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares are trading lower by 45% to 17 cents during Wednesday&#8217;s session after the company <a href="https://www.benzinga.com/pressreleases/25/03/b44137907/cutera-takes-steps-to-strengthen-financial-foundation-and-position-the-company-for-long-term-succe">announced a restructuring plan</a> involving filing &#8220;pre-packaged&#8221; Chapter 11 bankruptcy in Texas. The company says the restructuring will reduce its debt by over 90%—nearly $400 million—and raise $65 million in new funding.
What To Know: To facilitate the restructuring process, Cutera has filed &#8220;pre-packaged&#8221; Chapter 11 bankruptcy in Texas but will continue operating without disruption.
CEO Taylor Harris emphasized the move as a step toward sustainable growth with a stronger capital structure. The restructuring plan, already negotiated and approved by lenders, is expected to be completed within 60 days, after which Cutera will become a private company with investment firm backing. 
What Else: The company has also requested court approval to continue timely vendor payments. Its international entities remain unaffected by the filing. 
Cutera says the company meanwhile aims to maintain its commitment to innovation and customer service throughout the transition.
Read Also: <a href="https://www.benzinga.com/25/03/44138694/foot-locker-posts-q4-eps-beat-helped-by-comparable-sales-growth-and-margin-expansion">Foot Locker Q4 Earnings: EPS Beat, Sales Miss, Comps Up 2.6%, Margin Expansion And More</a>
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, CUTR has a 52-week high of $3.00 and a 52-week low of $0.16.

Cutera (CUTR) Shares Are Down 45% Today: What's Going On?

WIIM

Cutera shares are trading lower after the company announced it filed for Chapter 11.

CUTERA, INC., ("Cutera" or "the Company"), a leading provider of aesthetic and dermatology solutions, today announced that it is initiating a restructuring transaction with the support of a group of existing lenders, representing approximately 74% of the Company's notes, to strengthen its balance sheet and position Cutera for long-term success.
Through the transaction, Cutera will reduce its debt by nearly $400 million, or over 90%, and raise $65 million in new money from its existing lenders. To implement the transaction, Cutera has filed voluntary "pre-packaged" Chapter 11 cases in the U.S. Bankruptcy Court for the Southern District of Texas. Cutera will operate as usual throughout the court-supervised process and continue to provide best-in-class solutions to its customers around the globe without disruption.

Cutera Files for Chapter 11, Reduces Debt by $400M and Secures $65M in New Funding

<h3>Gainers</h3>
<ul>
<li>PureTech Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTC#NASDAQ">PRTC</a>) stock rose 30.9% to $25.0 during Monday's pre-market session. The market value of their outstanding shares is at $598.5 million. </li>
<li>Telix Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLX#NASDAQ">TLX</a>) shares increased by 21.88% to $22.0. The market value of their outstanding shares is at $7.3 billion. </li>
<li>Microbot Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBOT#NASDAQ">MBOT</a>) shares rose 18.43% to $3.02. The market value of their outstanding shares is at $84.6 million. </li>
<li>Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) shares rose 16.84% to $0.79. The market value of their outstanding shares is at $145.7 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares rose 12.74% to $0.49. The company's market cap stands at $9.9 million. </li>
<li>Solid Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLDB#NASDAQ">SLDB</a>) stock increased by 12.5% to $3.24. The company's market cap stands at $129.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pliant Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) shares declined by 57.6% to $3.3 during Monday's pre-market session. The company's market cap stands at $200.8 million. </li>
<li>Precipio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPO#NASDAQ">PRPO</a>) stock declined by 24.87% to $5.0. The market value of their outstanding shares is at $7.4 million. </li>
<li>Replimune Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REPL#NASDAQ">REPL</a>) stock fell 19.59% to $11.21. The company's market cap stands at $862.6 million. </li>
<li>Conduit Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDT#NASDAQ">CDT</a>) shares decreased by 17.55% to $2.35. The company's market cap stands at $3.6 million. </li>
<li>Cyclo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTH#NASDAQ">CYTH</a>) shares fell 15.13% to $1.01. The market value of their outstanding shares is at $33.0 million. </li>
<li>OptiNose (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTN#NASDAQ">OPTN</a>) stock declined by 12.05% to $5.11. The market value of their outstanding shares is at $51.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CYTH

MBOT

NKTR

OPTN

PLRX

PRPO

PRTC

REPL

SLDB

12 Health Care Stocks Moving In Monday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) shares rose 27.4% to $13.5 during Monday's pre-market session. The market value of their outstanding shares is at $702.3 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares rose 25.08% to $0.35. The market value of their outstanding shares is at $15.5 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares moved upwards by 23.0% to $0.44. The market value of their outstanding shares is at $52.6 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) shares moved upwards by 21.95% to $0.32. The market value of their outstanding shares is at $9.7 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares moved upwards by 15.06% to $0.47. The company's market cap stands at $4.0 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) stock rose 14.29% to $0.49. The company's market cap stands at $9.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) shares fell 45.3% to $0.08 during Monday's pre-market session. The market value of their outstanding shares is at $3.2 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares fell 16.29% to $4.01. The company's market cap stands at $232.1 million. </li>
<li>Annovis Bio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANVS#NYSE">ANVS</a>) shares decreased by 14.79% to $4.15. The company's market cap stands at $57.2 million. </li>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) stock fell 14.38% to $2.74. The market value of their outstanding shares is at $72.2 million. </li>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) stock fell 13.17% to $5.87. The market value of their outstanding shares is at $113.4 million. </li>
<li>Orchestra BioMed Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OBIO#NASDAQ">OBIO</a>) stock fell 12.22% to $4.6. The market value of their outstanding shares is at $173.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

ANVS

GHRS

HCWB

ICAD

IVVD

NVCT

Orchestra BioMed Holdings, Inc. - Ordinary Shares

OBIO

PRPH

VIRX

Cutera On Nov 19, Got Notice From Nasdaq On Failure To Satisfy A Continued Listing Rule Or Standard

Cutera shares are trading lower after the company reported mixed Q3 financial results.

Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) affirms FY2024 sales outlook from $140.00 million-145.00 million to $140.00 million-145.00 million.

Guidance

Cutera Affirms FY2024 Sales Guidance to $140.00M-145.00M  VS Est.141.53M

Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) reported quarterly losses of $(1.67) per share which missed the analyst consensus estimate of $(0.96) by 73.96 percent. The company reported quarterly sales of $32.500 million which beat the analyst consensus estimate of $32.086 million by 1.29 percent. This is a 30.07 percent decrease over sales of $46.478 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Cutera Q3 2024 Adj. EPS $(1.67) Misses $(0.96) Estimate, Sales $32.500M Beat $32.086M Estimate

<h3>Gainers</h3>
<ul>
<li>Gritstone Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTS#NASDAQ">GRTS</a>) shares rose 13.7% to $0.06 during Monday's after-market session. The market value of their outstanding shares is at $7.2 million. </li>
<li>Palatin Techs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PTN#AMEX">PTN</a>) stock increased by 6.11% to $0.92. The company's market cap stands at $17.8 million. </li>
<li>GRAIL (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAL#NASDAQ">GRAL</a>) shares rose 5.64% to $14.65. The market value of their outstanding shares is at $454.9 million. </li>
<li>Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) stock moved upwards by 5.45% to $0.75. The company's market cap stands at $15.1 million. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock moved upwards by 4.99% to $0.33. The market value of their outstanding shares is at $2.8 million. </li>
<li>Aura Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AURA#NASDAQ">AURA</a>) stock moved upwards by 4.93% to $9.79. The market value of their outstanding shares is at $485.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>INVO Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INVO#NASDAQ">INVO</a>) shares decreased by 8.9% to $1.13 during Monday's after-market session. The market value of their outstanding shares is at $4.4 million. </li>
<li>Dogwood Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DWTX#NASDAQ">DWTX</a>) stock fell 7.8% to $4.14. The company's market cap stands at $5.5 million. </li>
<li>Inhibikase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IKT#NASDAQ">IKT</a>) stock declined by 5.67% to $1.5. The market value of their outstanding shares is at $11.1 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares declined by 5.07% to $0.33. The market value of their outstanding shares is at $6.8 million. </li>
<li>Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) shares decreased by 4.89% to $6.81. The company's market cap stands at $227.2 million. </li>
<li>Biofrontera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFRI#NASDAQ">BFRI</a>) shares decreased by 4.89% to $0.78. The company's market cap stands at $4.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AURA

BFRI

CTCX

DWTX

GRAL

GRTS

INVO

OGEN

SERA

12 Health Care Stocks Moving In Monday's After-Market Session

Stephens &amp; Co. analyst George Sellers maintains Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) with a Overweight and lowers the price target from $10 to $5.

Price Target

Stephens & Co. Maintains Overweight on Cutera, Lowers Price Target to $5

Piper Sandler analyst Matt O'Brien reiterates Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) with a Neutral and lowers the price target from $3 to $1.

Reiteration

Piper Sandler Reiterates Neutral on Cutera, Lowers Price Target to $1

Cutera shares are trading lower after the company reported worse-than-expected Q2 revenue results and cut its FY24 revenue guidance.

Shares of Doximity, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>) rose sharply in today's pre-market trading reported better-than-expected first-quarter financial results and issued <a href="https://www.benzinga.com/news/earnings/24/08/40269788/doximity-stock-soars-on-q1-earnings-the-details">strong FY24 revenue guidance.</a>
Doximity's first-quarter revenue increased 17% year-over-year to $126.68 million, beating the consensus estimate of $119.92 million, according to Benzinga Pro. The company reported adjusted earnings of 28 cents per share, beating analyst estimates of 22 cents per share.
Doximity shares jumped 28.6% to $33.00 in pre-market trading.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Iteris, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITI#NASDAQ">ITI</a>) rose 61.7% to $6.92 in today's pre-market trading after the company agreed to be acquired by Almaviva for $335 million.</li>
<li>FSD Pharma Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUGE#NASDAQ">HUGE</a>) gained 53% to $0.14 in pre-market trading after gaining 16% on Thursday.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) gained 45.8% to $2.80 in pre-market trading. Nauticus Robotics partnered with Florida Atlantic University for cost-effective Aquanaut Mark 2 testing.</li>
<li>Avinger, Inc.. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) shares rose 28.3% to $1.54 in pre-market trading after reporting second-quarter results.</li>
<li>Iovance Biotherapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOVA#NASDAQ">IOVA</a>) gained 27.7% to $10.14 in pre-market trading after the company reported better-than-expected second-quarter financial results and issued Q3 product revenue guidance above estimates.</li>
<li>Clearmind Medicine Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) shares gained 27.7% to $1.52 in pre-market trading after declining around 8% on Thursday.</li>
<li>Marin Software Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRIN#NASDAQ">MRIN</a>) gained 27.1% to $2.30 in pre-market trading after the company announced AI-powered tool enhancements to its integrations with Reddit and X.</li>
<li>Babcock &amp; Wilcox Enterprises, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BW#NYSE">BW</a>) gained 22.5% to $1.36 following second-quarter results.</li>
<li>Sweetgreen, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SG#NYSE">SG</a>) jumped 22.3% to $32.11 in pre-market trading after the company reported better-than-expected second-quarter revenue results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>American Vanguard Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVD#NYSE">AVD</a>) shares dipped 30.8% to $5.66 in pre-market trading after the company reported worse-than-expected second-quarter financial results.</li>
<li>PubMatic, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PUBM#NASDAQ">PUBM</a>) shares declined 26.4% to $14.40 in pre-market trading after the company reported worse-than-expected second-quarter revenue results.</li>
<li>Cutera, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) shares declined 21.4% to $0.88 in pre-market trading after the company reported worse-than-expected second-quarter revenue results and cut its FY24 revenue guidance below estimates.</li>
<li>Nerdy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NRDY#NYSE">NRDY</a>) declined 20.1% to $1.27 in pre-market trading after the company reported worse-than-expected second-quarter revenue results.</li>
<li>FiscalNote Holdings, Inc.  (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOTE#NYSE">NOTE</a>) shares fell 18.3% to $1.12 in pre-market trading after reporting second-quarter results.</li>
<li>Eventbrite, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EB#NYSE">EB</a>) fell 17.1% to $3.15 in today's pre-market trading after the company reported worse-than-expected second-quarter revenue results and issued FY24 revenue guidance below estimates.</li>
<li>AMMO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POWW#NASDAQ">POWW</a>) shares fell 16.7% to $1.35 in pre-market trading after the company reported weak first-quarter sales.</li>
<li>Five9, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) fell 16.4% to $35.49 in pre-market trading after the company posted second-quarter results.</li>
<li>Trevena, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) fell 14.7% to $0.19 pre-market trading after the company reported second-quarter results.</li>
<li>Anew Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WENA#NASDAQ">WENA</a>) shares fell 10.1% to $1.15 in pre-market trading after gaining 17% on Thursday.</li>
</ul>
Now Read This: &lt;a href=&#8221;https://www.benzinga.com/news/earnings/24/04/38307448/investor-sentiment-decreases-further-s-p-500-falls-for-fourth-straight-session&#8221;&gt;&lt;em&gt; Investor Sentiment Decreases Further, S&amp;P 500 Falls For Fourth Straight Session&lt;/em&gt;&lt;/a&gt;

Trading Ideas

AVGR

CMND

DOCS

FIVN

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

IOVA

KITT

MRIN

NOTE

NRDY

POWW

PUBM

TRVN

WENA

Why Doximity Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket

Cutera Says Q2 Restructuring Resulted In $20M In Expense Savings On An Annualized Basis

Cutera shares are trading lower after the company reported worse-than-expected Q2 revenue results and cut its FY24 revenue guidance below estimates.

Cutera Sees FY24 Revenue $140M-$145M vs $161.81M Est. (Prior Outlook $160M-$170M)

Cutera (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CUTR#NASDAQ">CUTR</a>) reported quarterly sales of $34.400 million which missed the analyst consensus estimate of $38.695 million by 11.10 percent. This is a 43.81 percent decrease over sales of $61.218 million the same period last year.

Cutera Q2 Sales $34.400M Miss $38.695M Estimate

Cutera Announces Partnership With L'Oréal Japan To Exclusively Promote, Market, Sell And Distribute SkinCeuticals To Clinics In Japan

Press Releases

Cutera® Announces AviClear® Investor Webinar

Cutera® Appoints Jeryl L. Hilleman to Board of Directors

Cutera® Announces New Survey Data During Acne Awareness Month

Cutera® to Announce Second Quarter Results on August 8, 2024

Cutera® Announces Exclusive Distribution Agreement With L'Oréal® for SkinCeuticals® Products in Japan

Cutera® Announces Second Quarter 2024 Financial Results

Cutera® to Announce Third Quarter Results on November 7, 2024

Cutera® Announces Third Quarter 2024 Financial Results

Cutera® Announces Partnership with the Adaptive Training Foundation

Cutera Takes Steps to Strengthen Financial Foundation and Position the Company for Long-Term Success

Comments

Cutera

Intérêt court

Cutera (NASDAQ:CUTR) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL